Alvotech (NASDAQ:ALVO) has revealed 15 distinct programs aimed at key biologics, such as Xolair, Entyvio, Eylea HD, and ...
The introduction of biologics has changed treatment for many people with ulcerative colitis. Here’s what you need to know about the risks and benefits. Over the past 15 years, treatment options for ...
Large-cap biotech stocks face patent cliffs and biosimilar competition rather than AI-driven disruption, but companies like Amgen and AbbVie with broad product portfolios and multi-year pipeline ...
Humira (adalimumab) is a long-term maintenance medication used to manage chronic conditions like Crohn’s disease and rheumatoid arthritis. For many people, this drug is not a short-term fix but a ...
New findings explore the adalimumab biosimilar landscape, focusing on formulation, devices, and patient support programs that enhance treatment experiences. Not all adalimumab biosimilars are created ...
"SELECT-SWITCH is the first head-to-head trial comparing TNF inhibitor cycling with switching to the JAK inhibitor upadacitinib," said lead study investigator Eduardo Mysler, M.D., rheumatologist and ...
AbbVie ABBV expects to return to robust revenue growth in 2025, despite the U.S. loss of exclusivity (LOE) for its flagship drug Humira over two years ago. The drug, which went off-patent in January ...
Humira (adalimumab) is used to treat several autoimmune conditions. The drug typically stays in your system for a few months after your final dose. This article explains how long Humira may remain in ...
Medications for ulcerative colitis (UC) can treat and prevent flares, but they can also come with some uncomfortable side effects. For example, immunomodulators like azathioprine (Azasan) decrease UC ...
Patients with HS on adalimumab have a 53% higher risk of serious infections than those with psoriasis. HS patients are more prone to sepsis and genitourinary infections, with longer hospital stays.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results